New data provide key mechanistic insights into how TG4050 induces and sustains potent, CD8+ T cell responses in operable HNSCC[*] ...
Third quarter 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 millionRaises full year 2025 global revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback